Most of currently used cancer therapies is targeted into actively dividing cancer cells. Their elimination may temporarily remove cancer. Unfortunately, often under stress caused by therapy, part of cancer cells falls into quiescence state. When stressing conditions stops – after therapy, quiescent cancer cells may start to divide again. In this way quiescent cancer cells may be responsible for relapses in many types of cancer causing very difficult complete eradication of the tumor.
Selvita, together with Felicitex, is working on the development of therapeutic agents targeting quiescent cancer cells. Used as a single agents or in combinations with other drugs they will help to reach complete remission in several types of cancers.